Method and system of reduction of low frequency muscle stimulation during electrosurgical procedures

Information

  • Patent Grant
  • 8747399
  • Patent Number
    8,747,399
  • Date Filed
    Tuesday, April 6, 2010
    14 years ago
  • Date Issued
    Tuesday, June 10, 2014
    10 years ago
Abstract
Reduction of low frequency muscle stimulation during electrosurgical procedures. At least some of the illustrative embodiments are methods including: treating a target tissue with an electrosurgical wand comprising a plurality of active electrodes intermittently exposed to a rectifying electrical phenomenon; charging a first capacitance in series with a first electrode of the plurality of active electrodes, the charging during periods of time when the rectifying electrical phenomenon proximate the first electrode; charging a second capacitance in series with a second electrode of the plurality of active electrodes, the charging during periods of time when the rectifying electrical phenomenon is proximate the second electrode; charging a third capacitance in series with a third electrode of the plurality of active electrodes, the charging during periods of time when the rectifying electrical phenomenon is proximate the third electrode; and discharging, through the first electrode, the first capacitance, while simultaneously charging the second capacitance.
Description
BACKGROUND

Electrosurgical systems are used by physicians to perform specific functions during surgical procedures. For example, in an ablation mode electrosurgical systems use high frequency electrical energy to remove soft tissue such as sinus tissue, adipose tissue or meniscus, cartilage and/or sinovial tissue in a joint. In a coagulation mode, the electrosurgical device may aid the surgeon in reducing internal bleeding by assisting in the coagulation and/or sealing of vessels.


The electrosurgical procedures are performed using high frequency signals, as such high frequency signals provide the desired electrosurgical effect and in theory should not result in muscle or nerve stimulation of the patient. Stated another way, unwanted muscle and nerve stimulation is induced by low frequency and/or direct current (DC) signals flowing across or through muscle or nerve. Equipment constructed in accordance with the International Electrotechnical Commission (IEC) standards use DC blocking capacitance between the voltage generator of the electrosurgical controller and the patient to block DC signals flowing to or from the voltage generator.


However, in spite of being constructed in accordance with IEC standards, muscle and/or nerve stimulation is still noted in some patients.





BRIEF DESCRIPTION OF THE DRAWINGS

For a detailed description of exemplary embodiments, reference will now be made to the accompanying drawings in which:



FIG. 1A shows charging of a lumped blocking capacitance in an electrosurgical procedure;



FIG. 1B shows a discharging of a lumped blocking capacitance in an electrosurgical procedure;



FIG. 2 shows discrete capacitances in accordance with at least some embodiments;



FIG. 3 shows an electrosurgical system in accordance with at least some embodiments;



FIG. 4 shows a perspective view a portion of a wand in accordance with at least some embodiments;



FIG. 5 shows a cross-sectional view of a wand in accordance with at least some embodiments;



FIG. 6 shows both an elevation end-view (left) and a cross-sectional view (right) of a wand connector in accordance with at least some embodiments;



FIG. 7 shows both an elevation end-view (left) and a cross-sectional view (right) of a controller connector in accordance with at least some embodiments;



FIG. 8 shows an electrical block diagram of an electrosurgical controller in accordance with at least some embodiments; and



FIG. 9 shows a method in accordance with at least some embodiments.





NOTATION AND NOMENCLATURE

Certain terms are used throughout the following description and claims to refer to particular system components. As one skilled in the art will appreciate, companies that design and manufacture electrosurgical systems may refer to a component by different names. This document does not intend to distinguish between components that differ in name but not function.


In the following discussion and in the claims, the terms “including” and “comprising” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to . . . .” Also, the term “couple” or “couples” is intended to mean either an indirect or direct connection. Thus, if a first device couples to a second device, that connection may be through a direct connection or through an indirect electrical connection via other devices and connections.


Reference to a singular item includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural references unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement serves as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Lastly, it is to be appreciated that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.


“Active electrode” shall mean an electrode of an electrosurgical wand which produces an electrically-induced tissue-altering effect when brought into contact with, or close proximity to, a tissue targeted for treatment, and/or an electrode having a voltage induced thereon by a voltage generator.


“Return electrode” shall mean an electrode of an electrosurgical wand which serves to provide a current flow path for electrons with respect to an active electrode, and/or an electrode of an electrical surgical wand which does not itself produce an electrically-induced tissue-altering effect on tissue targeted for treatment.


“Rectifying electrical phenomenon” shall mean arcing, ionization or plasma creation proximate to an active electrode where the arcing, ionization or plasma has at least a slight electrical rectifying property.


Where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such material by virtue of prior invention.


DETAILED DESCRIPTION

Before the various embodiments are described in detail, it is to be understood that this invention is not limited to particular variations set forth herein as various changes or modifications may be made, and equivalents may be substituted, without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


The inventors of the present specification have uncovered a reason for parasitic stimulation of muscle and nerves of a patient by DC and/or low frequency signals in spite of electrosurgical systems using high frequency signals and a lumped blocking capacitance in accordance with IEC Standards. FIG. 1A illustrates a simplified system in order to explain the presence of parasitic DC and low frequency signals. In particular, FIG. 1A illustrates a voltage generator 100 having an active terminal 102 and a return terminal 104. The voltage generator is coupled to a plurality of active electrodes 106, 108 and 110, and as illustrated a single return electrode 112. In accordance with IEC standards the illustrative system of FIG. 1A has a direct current (DC) blocking capacitance in the form of a single DC blocking capacitor 114 coupled between the active terminal 102 and the various active electrodes.


In operation, each active electrode 106, 108 and 110 creates an electrical phenomenon 116 proximate to the active electrodes. The electrical phenomenon is in most cases an electrical arcing, ionization and/or plasma. Regardless of the precise nature of the electrical phenomenon, the electrical phenomenon has an inherent electrical rectifying characteristic, and thus is termed herein a “rectifying electrical phenomenon.” The rectifying nature of the electrical phenomenon is illustrated by the diode 118 shown within the electrical phenomenon 116; however, it is to be understood that the rectifying electrical phenomenon produces a rectifying effect associated with each active electrode when the rectifying electrical phenomenon is proximate to each active electrode. Moreover, the rectifying electrical phenomenon is neither itself a diode, nor is the rectifying electrical phenomenon as efficient at rectification as a diode coupled between the electrodes. Rather, the rectifying effect is slight, and although shown to favor electrical current flow from the return electrode 112 to the active electrode 110, in some situations rectifying electrical phenomenon favors current flow from the active electrode(s) to the return electrode(s) 112. The rectifying electrical phenomenon results in a charging of the DC blocking capacitor 114. In particular, the rectifying electrical phenomenon, when present, builds a DC bias on the capacitor 114, as illustrated by the line 120 and “plus” symbol on the capacitor 114 plate. The charge continues to accumulate through each active electrode 106, 108 and 110 during periods of time when the rectifying electrical phenomenon is proximate each active electrode, and thus may build for extended periods (relative to the period of the AC signal generated by the voltage generator).


However, the rectifying electrical phenomenon is not continuous during electrosurgical procedures. That is, the rectifying electrical phenomenon is present for a time, and then may cease for a time, depending on factors such as proximity of the active electrodes to bodily tissue, and the amount and location of conductive fluid relative to the active electrode, just to name a few. The inventors have found that during periods of time when the rectifying electrical phenomenon is absent, if an active electrode physically contacts the patient, an electrical circuit is created which discharges the charge stored on the blocking capacitor 114 through the patient. FIG. 1B illustrates such a situation. In particular, FIG. 1B illustrates the situation where the rectifying electrical phenomenon has ceased proximate to active electrodes 106, 108 and 110, and further that active electrode 108 contacts the patient 122. Having active electrode 108 complete the electrical circuit is merely illustrative, as any one active electrode singly, or two more active electrodes together, may complete the electrical circuit by contacting the tissue and/or fluid of the patient. In contacting the patient 122, a completed electrical circuit is created such that the charge stored on the DC blocking capacitor 114 is discharged through the patient, as shown by line 124. The charge stored on the DC blocking capacitor 114 is a DC charge, and thus discharging the DC blocking capacitor can be considered a DC current flow. Moreover, if the electrical circuit through the patient is created periodically (e.g., 100 times a second or less), then the discharging of the DC blocking capacitor appears as a low frequency (e.g., 100 Hertz) parasitic stimulation.


Thus, having the DC blocking capacitance lumped as shown in FIGS. 1A and 1B results in large energy storage capability for the DC blocking capacitance, and further results in each and every active electrode that is involved in completing and electrical circuit discharging the energy through the patient.


In order to at least partially address these issues, electrosurgical systems in accordance with the various embodiments distribute the DC blocking capacitance across active electrodes. FIG. 2 illustrates such a system. In particular, rather than lumping the DC blocking capacitance, the system comprises a plurality of capacitors 200, 202 and 204, and wherein the plurality of capacitors are electrically coupled one each in series with a respective electrical lead and active electrode 106, 108, and 110 as illustrated by FIG. 2. While FIG. 2 shows only three electrical leads coupled to active electrodes, two or more active electrodes are contemplated, and in some cases 23 active electrodes each having a 2.2 nano-Farad (nF) capacitor in series therewith. While at first blush the circuit of FIG. 2 may seem electrically equivalent to the lumped DC blocking capacitance 114 of FIGS. 1A and 1B, a surprising result is obtained in embodiments constructed as in FIG. 2.


In particular, the inventors of the present specification have found that the rectifying electrical phenomenon is discontinuous during electrosurgical procedures with respect to each active electrode considered individually. That is, for a particular active electrode the rectifying electrical phenomenon randomly is present for a time, then ceases for a time, and then again present. During periods of time when the rectifying electrical phenomenon has ceased for the particular active electrode, other active electrodes may continue to have their respective rectifying electrical phenomenon present. For example, active electrode 110 may have its respective rectifying electrical phenomenon 206 present, but active electrodes 106 and 108 may not. Thus, in the illustrative situation capacitor 204 may be being charged with a DC bias voltage, while capacitors 200 and 202 retain their charge and/or discharge through the patient. The randomization of the discharge states of the capacitors 200, 202 and 204 surprisingly results in an effective capacitance seen by the patient during electrosurgical procedures lower than the sum of the capacitances in parallel, and thus lower than the electrosurgical systems in FIGS. 1A and 1B.


Although the inventors do not wish to be tied to any particular physical interpretation that results in the lower effective capacitance, it is believed that a portion of the lower effective capacitance is based on the lower amount of energy that can be discharged through each active electrode. While in the systems of FIGS. 1A and 1B any active electrode could discharge the full energy storage of the DC blocking capacitor 114, in the embodiments of FIG. 2 each electrode can only discharges its respective capacitor (e.g., the energy stored on capacitor 200 can only be discharged through active electrode 106). Moreover, with lower energy stored on each capacitor, a capacitor may discharge more quickly, rather than partial discharges that may occur for a lumped DC blocking capacitance. Relatedly, another physical aspect that may result in the lower effective capacitance is limited charging pathways for each capacitor 200, 202 and 204. In particular, the DC current flowing through an active electrode caused by the rectifying electrical phenomenon can only charge the respective capacitor of the active electrode. Thus, the amount of charge accumulated on a capacitor during periods of time when the rectifying electrical phenomenon associated with a particular active electrode may be lower than if electrical current through any or all active electrodes can contribute to the stored charge.


The embodiments of FIG. 2 do not intimate any particular physical location of the capacitors coupled one each in series with a respective electrical lead (or respective active electrode), and the physical placement may vary from embodiment-to-embodiment. The specification now turns to various embodiments of the electrosurgical controllers and wands, and various illustrative locations for physical placement of the respective capacitors.



FIG. 3 illustrates an electrosurgical system 300 in accordance with at least some embodiments. In particular, the electrosurgical system comprises an electrosurgical wand 302 (hereinafter “wand”) coupled to an electrosurgical controller 304 (hereinafter “controller”). The wand 302 comprises an elongate shaft 306 that defines distal end 308 where at least some electrodes are disposed. The elongate shaft 306 further defines a handle or proximal end 310, where a physician grips the wand 302 during surgical procedures. The wand 302 further comprises a flexible multi-conductor cable 312 housing a plurality of electrical leads (not specifically shown in FIG. 3), and the flexible multi-conductor cable 312 terminates in a wand connector 314. Though not visible in the FIG. 3, in some embodiments the wand 302 has an internal passage fluidly coupled to a flexible tubular member 316. The internal passage and flexible tubular member 316 may be used as a conduit to supply conductive fluid proximate to the distal end 308, or the internal passage and flexible tubular member may be used to aspirate the area proximate to the distal end 308 of the wand 302.


As shown in FIG. 3, the wand 302 couples to the controller 304, such as by a controller connector 320, on an outer surface of an enclosure 322 (in the illustrative case of FIG. 3 the controller connector 320 is on a front surface). A display device or interface panel 324 is visible through the enclosure 322, and in some embodiments a user may select operational modes of the controller 304 by way of the interface device 324 and related buttons 326.


Still referring to FIG. 3, in some embodiments the electrosurgical system 300 also comprises a foot pedal assembly 330. The foot pedal assembly 330 may comprise one or more pedal devices 332 and 334, a flexible multi-conductor cable 336 and a pedal connector 338. While only two pedal devices 332, 334 are shown, any number of pedal devices may be implemented. The enclosure 322 of the controller 304 may comprise a corresponding connector 340 that couples to the pedal connector 338. A physician may use the foot pedal assembly 330 to control various aspects of the controller 304, such as the operational mode. For example, a pedal device, such as pedal device 332, may be used for on-off control of the application of radio frequency (RF) energy to the wand 302, and more specifically for control of energy in an ablation mode. A second pedal device, such as pedal device 334, may be used to control and/or set the operational mode of the electrosurgical system. For example, actuation of pedal device 334 may switch between ablation mode and a coagulation mode. Alternatively, pedal device 334 may be used to control the application of RF energy to wand 302 in a coagulation mode. The pedal devices may also be used to change the voltage level delivered to wand 302.


The electrosurgical system 300 of the various embodiments may have a variety of operational modes. One such mode employs Coblation® technology. In particular, the assignee of the present disclosure is the owner of Coblation® technology. Coblation® technology involves the application of a RF signal between one or more active electrodes and one or more return electrodes of the wand 302 to develop high electric field intensities in the vicinity of the target tissue. The electric field intensities may be sufficient to vaporize an electrically conductive fluid over at least a portion of the one or more active electrodes in the region between the one or more active electrodes and the target tissue. The electrically conductive fluid may be inherently present in the body, such as blood, or in some cases extracellular or intracellular fluid. In other embodiments, the electrically conductive fluid may be a liquid or gas, such as isotonic saline. In some embodiments the electrically conductive fluid is delivered in the vicinity of the active electrodes and/or to the target site by the wand 302, such as by way of the internal passage and flexible tubular member 316.


When the electrically conductive fluid is heated to the point that the atoms of the fluid vaporize faster than the atoms recondense, a gas is formed. When sufficient energy is applied to the gas, the atoms collide with each other causing a release of electrons in the process, and an ionized gas or plasma is formed (the so-called “fourth state of matter”). Stated otherwise, plasmas may be formed by heating a gas and ionizing the gas by driving an electric current through the gas, or by directing electromagnetic waves into the gas. The methods of plasma formation give energy to free electrons in the plasma directly, electron-atom collisions liberate more electrons, and the process cascades until the desired degree of ionization is achieved. A more complete description of plasma can be found in Plasma Physics, by R. J. Goldston and P. H. Rutherford of the Plasma Physics Laboratory of Princeton University (1995), the complete disclosure of which is incorporated herein by reference.


As the density of the plasma becomes sufficiently low (i.e., less than approximately 1020 atoms/cm3 for aqueous solutions), the electron mean free path increases such that subsequently injected electrons cause impact ionization within the plasma. When the ionic particles in the plasma layer have sufficient energy (e.g., 3.5 electron-Volt (eV) to 5 eV), collisions of the ionic particles with molecules that make up the target tissue break molecular bonds of the target tissue, dissociating molecules into free radicals which then combine into gaseous or liquid species. Often, the electrons in the plasma carry the electrical current or absorb the electromagnetic waves and, therefore, are hotter than the ionic particles. Thus, the electrons, which are carried away from the target tissue toward the active or return electrodes, carry most of the plasma's heat, enabling the ionic particles to break apart the target tissue molecules in a substantially non-thermal manner.


By means of the molecular dissociation (as opposed to thermal evaporation or carbonization), the target tissue is volumetrically removed through molecular dissociation of larger organic molecules into smaller molecules and/or atoms, such as hydrogen, oxygen, oxides of carbon, hydrocarbons and nitrogen compounds. The molecular dissociation completely removes the tissue structure, as opposed to dehydrating the tissue material by the removal of liquid within the cells of the tissue and extracellular fluids, as occurs in related art electrosurgical desiccation and vaporization. A more detailed description of the molecular dissociation can be found in commonly assigned U.S. Pat. No. 5,697,882, the complete disclosure of which is incorporated herein by reference.


In addition to the Coblation® mode, the electrosurgical system 300 of FIG. 3 is also useful for sealing larger arterial vessels (e.g., on the order of about 1 mm in diameter), when used in what is known as a coagulation mode. Thus, the system of FIG. 3 may have an ablation mode where RF energy at a first voltage is applied to one or more active electrodes sufficient to effect molecular dissociation or disintegration of the tissue, and the system of FIG. 3 has a coagulation mode where RF energy at a second, lower voltage is applied to one or more active electrodes (either the same or different electrode(s) as the ablation mode) sufficient to heat, shrink, seal, fuse, and/or achieve homeostasis of severed vessels within the tissue.


The energy density produced by electrosurgical system 300 at the distal end 308 of the wand 302 may be varied by adjusting a variety of factors, such as: the number of active electrodes; electrode size and spacing; electrode surface area; asperities and/or sharp edges on the electrode surfaces; electrode materials; applied voltage; electrical conductivity of the fluid in contact with the electrodes; density of the conductive fluid; and other factors. Accordingly, these factors can be manipulated to control the energy level of the excited electrons. Since different tissue structures have different molecular bonds, the electrosurgical system 300 may be configured to produce energy sufficient to break the molecular bonds of certain tissue but insufficient to break the molecular bonds of other tissue. For example, fatty tissue (e.g., adipose) has double bonds that require an energy level higher than 4 eV to 5 eV (i.e., on the order of about 8 eV) to break. Accordingly, the Coblation® technology in some operational modes does not ablate such fatty tissue; however, the Coblation® technology at the lower energy levels may be used to effectively ablate cells to release the inner fat content in a liquid form. Other modes may have increased energy such that the double bonds can also be broken in a similar fashion as the single bonds (e.g., increasing voltage or changing the electrode configuration to increase the current density at the electrodes). A more complete description of the various phenomena can be found in commonly assigned U.S. Pat. Nos. 6,355,032, 6,149,120 and 6,296,136, the complete disclosures of which are incorporated herein by reference.



FIG. 4 illustrates the distal end 308 of illustrative wand 302. In particular, in some embodiments the elongate shaft 306 is made of an inorganic insulating (i.e., non-conductive) material. In other embodiments, the elongate shaft 306 comprises a conductive material, but is covered with an insulating material. The distal end 308 further comprises a plurality of electrodes. For example, in the illustrative case of FIG. 4, seven electrodes 402, 404, 406, 408, 410, 412 and 414 are shown; however, three or more electrodes may be equivalently used. As illustrated in FIG. 4, the electrodes may take many forms. Electrodes 402, 404 and 406 are illustrative of wire-type electrodes that protrude slightly from the end 416 of the elongate shaft 306. The wire-type electrodes 402, 404 and 406 may be used, for example, singly or in combination to be the electrodes to which the RF energy is applied in the ablation mode. Electrodes 408, 410 are disposed on a surface 418 of the distal end 308, and the electrodes 408, 410 span a certain circumferential distance. Electrodes 412, 414 are similar to electrodes 408, 410, but span a smaller circumferential distance. Other electrode types, such as button electrodes (i.e., round electrodes), arrays of button electrodes, or screen electrodes, may be equivalently used.


Still referring to FIG. 4, in some embodiments the wand 302 has an internal lumen 450 that fluidly couples to the flexible tubular member 316 (FIG. 1). In some modes of operation, the internal lumen 450 is used to supply conductive fluid to the target area to aid in implementing the Coblation® technology. In other modes of operation, the internal lumen 450 may be used to aspirate the area near the distal end 308 of the wand 302, such as when sufficient conductive fluid is already present at the target location and ablation is taking place, or to remove byproducts of the ablation process.



FIG. 5 shows a cross-sectional view of wand 302 in accordance with at least some embodiments. In particular, FIG. 5 illustrates the elongate shaft 306 comprising distal end 308 and proximal end 310. Distal end 308 comprises a plurality of electrodes 500, and while the electrodes 500 are similar to the electrodes of FIG. 4, electrodes 500 are not necessarily the same as those of FIG. 4. Each electrode 500 has an electrical lead associated therewith that runs through the elongate shaft 306 to the flexible multi-conductor cable 312. In particular, electrode 500A has dedicated electrical lead 502A which runs within the elongate shaft to the become part of cable 312. Similarly, electrode 500B has dedicated electrical lead 502B which runs within the elongate shaft 306 to become part of cable 312. Illustrative electrodes 500C and 500D likewise have dedicated electrical leads 502C and 502D which run within the elongate shaft 306 to become part of cable 312. In some embodiments, the elongate shaft 306 has dedicated internal passages (in addition to internal lumen 450) through which the electrical leads 502 run. In other embodiments, the electrical leads 502 are cast within the material that makes up the elongate shaft.



FIG. 5 also illustrates internal lumen 450 having an aperture 504 fluidly coupled to the flexible tubular member 316 on the proximal end 310. In other embodiments, the fluid coupling of the internal lumen 450 to the flexible tubular member 316 may be between the distal end 308 and proximal end 310. The internal lumen 450 is used in some embodiments to supply conductive fluid through the aperture 504 to the target area, and in other embodiments the internal lumen 450 is used for aspiration of ablated tissue fragments and/or molecules. In some embodiments, an electrode 502D may be disposed within the internal lumen 450 proximate to the aperture 504. An electrode 500D within the internal lumen 450 may, for example, be selected as either an active or return electrode in an ablation mode, and may aid in disassociation of tissue pieces into smaller pieces during ablation and aspiration procedures.


In accordance with at least some embodiments, the plurality of capacitors coupled one each in series with a respective electrical lead may be disposed within the wand 302 as shown in FIG. 5. In particular, for the illustrative four active electrodes 500A-500D, there may be a respective four capacitors 510A-510D disposed within wand 302 (and as illustrated in the handle 310). In other embodiments the capacitors may be disposed within the elongate shaft 306.



FIG. 5 also illustrates embodiments where the plurality of capacitors coupled one each in series with a respective electrical lead may be disposed within the multi-conductor cable 312. In particular, for the illustrative four active electrodes 500A-500D, there may be a respective four capacitors 512A-512D disposed within multi-conductor cable 312. While FIG. 5 shows capacitors both in the multi-conductor cable 312 and in the wand 302, and an electrosurgical system would be operational as illustrated in FIG. 5, when disposing the plurality of capacitors outside the controller 304 either location alone will suffice.


In addition to the distributed capacitors, current-limiting resistors may be selected. The current-limiting resistors will have a large positive temperature coefficient of resistance so that, as the current level begins to rise for any individual active electrode in contact with a low resistance medium (e.g., saline or blood), the resistance of the current limiting resistor increases significantly, thereby reducing the power delivery from the active electrode into the low resistance medium. In some embodiments, the current limited devices may reside within the elongate shaft 306, or may reside within the cable 312.


As illustrated in FIG. 3, flexible multi-conductor cable 312 (and more particularly its constituent electrical leads 502) couple to the wand connector 314. Wand connector 314 couples the controller 304, and more particularly the controller connector 320. FIG. 6 shows both a cross-sectional view (right) and an end elevation view (left) of wand connector 314 in accordance with at least some embodiments. In particular, wand connector 314 comprises a tab 600. Tab 600 works in conjunction with a slot on controller connector 320 (shown in FIG. 6) to ensure that the wand connector 314 and controller connector 320 only couple in one relative orientation. The illustrative wand connector 314 further comprises a plurality of electrical pins 602 protruding from wand connector 114. The electrical pins 402 are coupled one each to a single electrical lead 502. Stated otherwise, each electrical pin 602 couples to a single electrical lead 502, and thus each illustrative electrical pin 602 couples to a single electrode 500 (FIG. 5). While FIG. 6 shows only four illustrative electrical pins, in some embodiments 26 or more electrical pins may be present in the wand connector 314.



FIG. 7 shows both a cross-sectional view (right) and an end elevation view (left) of controller connector 320 in accordance with at least some embodiments. In particular, controller connector 320 comprises a slot 700. Slot 700 works in conjunction with a tab 600 on wand connector 314 (shown in FIG. 6) to ensure that the wand connector 314 and controller connector 320 only couple in one orientation. The illustrative controller connector 320 further comprises a plurality of electrical pins 702 residing with respective holes of controller connector 320. The electrical pins 702 may be individually coupled to a relay within the controller 304 (discussed more thoroughly below). When wand connector 314 and controller connector 320 are coupled, each electrical pin 702 couples to a single electrical pin 602, and thus each illustrative electrical pin 702 couples to a single electrode 500 (FIG. 5). While FIG. 7 shows only four illustrative electrical pins, in some embodiments 26 or more electrical pins may be present in the wand connector 120.


While illustrative wand connector 314 is shown to have the tab 600 and male electrical pins 602, and controller connector 320 is shown to have the slot 700 and female electrical pins 702, in alternative embodiments the wand connector has the female electrical pins and slot, and the controller connector 120 has the tab and male electrical pins. In other embodiments, the arrangement of the pins within the connectors may enable only a single orientation for connection of the connectors, and thus the tab and slot arrangement may be omitted. In yet still other embodiments, other mechanical arrangements to ensure the wand connector and controller connector couple in only one orientation may be equivalently used.



FIG. 8 illustrates a controller 304 in accordance with at least some embodiments. In particular, the controller 304 in accordance with at least some embodiments comprises a processor 800. The processor 800 may be a microcontroller, and therefore the microcontroller may be integral with read-only memory (ROM) 802, random access memory (RAM) 804, digital-to-analog converter (D/A) 806, digital outputs (D/O) and digital inputs (D/I) 810. The processor 800 may further provide one or more externally available peripheral busses, such as a serial bus (e.g., I2C), parallel bus, or other bus and corresponding communication mode. The processor 800 may further be integral with a communication logic 812 to enable the processor 800 to communicate with external devices, as well as internal devices, such as display device 324. Although in some embodiments the controller 304 may implement a microcontroller, in yet other embodiments the processor 800 may be implemented as a standalone central processing unit in combination with individual RAM, ROM, communication, D/A, D/O and D/I devices, as well as communication port hardware for communication to peripheral components.


ROM 802 stores instructions executable by the processor 800. In particular, the ROM 802 may comprise a software program that implements various operation modes, as well as interfacing with the user by way of the display device 324, the foot pedal assembly 330 (FIG. 1), and/or a speaker assembly 870. The RAM 804 may be the working memory for the processor 800, where data may be temporarily stored and from which instructions may be executed. Processor 800 couples to other devices within the controller 304 by way of the D/A converter 806 (e.g., the voltage generator 816), digital outputs 808 (e.g., electrically controlled switches 820), digital inputs 810 (e.g., push button switches 326, and the foot pedal assembly 330 (FIG. 1)), communication device 812 (e.g., display device 324), and other peripheral devices. The other peripheral devices may comprise electrode relays and/or switches, devices to set desired voltage generator 816 output voltage, and other secondary devices internal to the generator.


Voltage generator 816 generates selectable alternating current (AC) voltages that are applied to the electrodes of the wand 302. In some embodiments, the voltage generator defines an active terminal 824 and a return terminal 826. The active terminal 824 is the terminal upon which the voltages and electrical currents are induced by the voltage generator 816, and the return terminal 826 provides a return path for electrical currents. In some embodiments, the return terminal 826 may provide a common or ground being the same as the common or ground within the balance of the controller 304 (e.g., the common 828 used on push-buttons 826), but in other embodiments the voltage generator 816 may be electrically “floated” from the balance of the supply power in the controller 304, and thus the return terminal 826, when measured with respect to the common (e.g., common 828) within the controller 304, may show a voltage difference; however, an electrically floated voltage generator 816 and thus the potential for voltage readings on the return terminal 816 does not negate the return terminal status of the terminal 826 relative to the active terminal 824.


The voltage generated and applied between the active terminal 824 and return terminal 826 by the voltage generator 616 is a RF signal that, in some embodiments, has a frequency of between about 5 kilo-Hertz (kHz) and 20 Mega-Hertz (MHz), in some cases being between about 30 kHz and 2.5 MHz, preferably being between about 50 kHz and 500 kHz, often less than 350 kHz, and often between about 100 kHz and 200 kHz. In some applications, a frequency of about 100 kHz is useful because target tissue impedance is much greater at 100 kHz. In other applications, such as procedures in or around the heart or head and neck, higher frequencies may be desirable (e.g., 400-600 kHz).


The RMS (root mean square) voltage generated by the voltage generator 816 may be in the range from about 5 Volts (V) to 1000 V, preferably being in the range from about 10 V to 500 V, often between about 10 V to 400 V depending on the active electrode size, the operating frequency and the operation mode of the particular procedure or desired effect on the tissue (i.e., contraction, coagulation, cutting or ablation). The peak-to-peak voltage generated by the voltage generator 816 for ablation or cutting in some embodiments is a square wave form in the range of 10 V to 2000 V and in some cases in the range of 100 V to 1800 V and in other cases in the range of about 28 V to 1200 V, often in the range of about 100 V to 320V peak-to-peak (again, depending on the electrode size, number of electrodes the operating frequency and the operation mode). Lower peak-to-peak voltage is used for tissue coagulation, thermal heating of tissue, or collagen contraction and may be in the range from 50 V to 1500V, preferably 100 V to 1000 V and more preferably 60 V to 130 V peak-to-peak (again, these values are computed using a square wave form).


The voltage and current generated by the voltage generator 816 may be delivered in a series of voltage pulses or AC voltage with a sufficiently high frequency (e.g., on the order of 5 kHz to 20 MHz) such that the voltage is effectively applied continuously (as compared with, e.g., lasers claiming small depths of necrosis, which are pulsed about 10 Hz to 20 Hz). In addition, the duty cycle (i.e., cumulative time in any one-second interval that energy is applied) of the square wave voltage produced by the voltage generator 816 is on the order of about 50% for some embodiments as compared with pulsed lasers which may have a duty cycle of about 0.0001%. Although square waves are generated and provided in some embodiments, the various embodiments may be equivalently implemented with many applied voltage waveforms (e.g., sinusoidal, triangular).


Still referring to the voltage generator 816, the voltage generator 816 delivers average power levels ranging from several milliwatts to hundreds of watts per electrode, depending on the voltage applied to the target electrode for the target tissue being treated, and/or the maximum allowed temperature selected for the wand 102. The voltage generator 816 is configured to enable a user to select the voltage level according to the specific requirements of a particular neurosurgery procedure, cardiac surgery, arthroscopic surgery, dermatological procedure, ophthalmic procedures, open surgery or other endoscopic surgery procedure. For cardiac procedures and potentially for neurosurgery, the voltage generator 816 may have a filter that filters leakage voltages at frequencies below 100 kHz, particularly voltages around 60 kHz. Alternatively, a voltage generator 816 configured for higher operating frequencies (e.g., 300 kHz to 600 kHz) may be used in certain procedures in which stray low frequency currents may be problematic. A description of one suitable voltage generator 616 can be found in commonly assigned U.S. Pat. Nos. 6,142,992 and 6,235,020, the complete disclosure of both patents are incorporated herein by reference for all purposes.


In accordance with at least some embodiments, the voltage generated 816 is configured to limit or interrupt current flow when low resistivity material (e.g., blood, saline or electrically conductive gel) causes a lower impedance path between the return electrode(s) and the active electrode(s). Further still, in some embodiments the voltage generator 816 is configured by the user to be a constant current source (i.e., the output voltage changes as function of the impedance encountered at the wand 302).


In some embodiments, the various operational modes of the voltage generator 816 may be controlled by way of digital-to-analog converter 806. That is, for example, the processor 800 may control the output voltage by providing a variable voltage to the voltage generator 816, where the voltage provided is proportional to the voltage generated by the voltage generator 816. In other embodiments, the processor 800 may communicate with the voltage generator by way of one or more digital output signals from the digital output 808 device, or by way of packet based communications using the communication 812 device (the alternative embodiments not specifically shown so as not to unduly complicate FIG. 8).


In addition to controlling the output of the voltage generator 816, in accordance with at least some embodiments the controller 304 is also configured to selectively electrically couple the active terminal 824 singly or in combination to the electrodes of the wand (by way of the electrical pins of the controller connector 320). Likewise, in the various embodiments, the controller 304 is also configured to selectively electrically couple the return terminal 826 singly or in combination to the electrodes of the wand (again by way of the electrical pins of the controller connector 320). In order to perform the selective coupling, the controller 304 implements a control circuit 830, shown in dashed lines in FIG. 8. For convenience of the figure the control circuit has two parts, 830A and 830B, but the two parts nevertheless comprise the control circuit 830. In particular, the control circuit 830 comprises the processor 800, voltage controlled switches 820 and mechanic relays K1-K6. The coils of relays K1-K6 are shown within portion 830A, while the contacts for each mechanical relay are shown within portion 830B. The correlation between the coils for mechanical relays K5 and K6 and the contacts for mechanical relays K5 and K6 are shown by dashed arrow-headed lines 850 and 852 respectively. The correlation between the remaining coils and contacts is not specifically shown with arrow-headed lines so as not to unduly complicate the figure; however, the correlation is noted by way of corresponding references.


In accordance with at least some embodiments, at least three electrodes of the wand 302 are separately electrically coupled to the controller 304. Thus, the description of FIG. 8 is based on three separately electrically coupled electrodes, but it will be understood that three or more separately electrically coupled electrodes may be used. The electrical pin of the controller connector 320 for each electrode is configured to be selectively coupled to either the active terminal 824 or the return terminal 826. For example, the electrical lead configured to couple illustrative electrode 1 of FIG. 8 couples to the normally open (NO) contact terminals for the mechanical relays K1 and K2. The other side of the normally open contact for mechanical relay K1 couples to the active terminal 824 by way of capacitor 880A, while the other side of the normally open contact for the mechanical relay K2 couples to the return terminal 626. Thus, by selectively activating mechanical relay K1 or mechanical relay K2, electrode 1 can be either an active or return electrode in the surgical procedure. Alternatively, both relays can remain inactivated, and thus electrode 1 may remain unconnected.


Similarly, the electrical lead configured to couple illustrative electrode 2 couples to the normally open contact terminals for the mechanical relays K3 and K4. The other side of the normally open contact for mechanical relay K3 couples to the active terminal 824 by way of capacitor 880B, while the other side of the normally open contact for the mechanical relay K4 couples to the return terminal 826. Thus, by selectively activating mechanical relay K3 or mechanical relay K4, electrode 2 can be either an active or return electrode in the surgical procedure. Alternatively, both relays K3 and K4 can remain inactivated, and thus electrode 2 may remain unconnected. Finally with respect to the illustrative electrode 3, the electrical lead configured to couple to illustrative electrode 3 couples to the normally open contact terminals for the mechanical relays K5 and K6. The other side of the normally open contact for mechanical relay K5 couples to the active terminal 824 by way of capacitor 880C, while the opposite side of the normally open contact for the mechanical relay K6 couples to the return terminal 826. Thus, by selectively activating mechanical relay K5 or mechanical relay K6, electrode 3 can be either an active or return electrode in the surgical procedure. Alternatively, both relays can remain inactivated, and thus electrode 3 may remain unconnected.


In accordance with at least some embodiments, mechanical relays K1-K6 are selectively activated (by way of their respective coils 834) by voltage controlled switches 820. For example, when the control circuit 830 desires to couple the active terminal to electrode 1, the voltage controlled switch 820A is activated, which allows current to flow through the coil 834A of mechanical relay K1. Current flow through the coil 834 activates the relay, thus closing (making conductive) the normally open contacts. Similarly, the control circuit 830 may selectively activate any of the voltage controlled switches 820, which in turn activate respective mechanical relays K1-K6. In accordance with at least some embodiments, each mechanical relay is a part number JW1FSN-DC 12V relay available from Panasonic Corporation of Secaucus, N.J.; however, other relays may be equivalently used. Moreover, while FIG. 8 illustrates the use of field effect transistors as the voltage controlled switches 820 to control the current flow through coils of the mechanical relays, other devices (e.g., transistors, or if coils use AC driving current, triacs) may be equivalently used. Further still, in embodiments where the digital outputs 808 have sufficient current carrying capability, the voltage controlled switches may be omitted.



FIG. 8 also illustrates that the capacitors for each electrode may reside within the controller 304. In particular, capacitors 880 are representative of capacitors coupled one each in series with each electrode. It is noted that if the capacitors reside within the controller as shown in FIG. 8, the capacitors in the multi-conductor cable 312 and/or the capacitors in wand 302 may be omitted. While FIG. 8 shows the capacitors as residing between the active electrode 824 and the respective relay contacts, in other embodiments the capacitors may reside between the relay contacts and the connector 320.



FIG. 9 illustrates a method in accordance with at least some embodiments. In particular, the method starts (block 900) and proceeds to treating a target tissue with an electrosurgical wand comprising a plurality of active electrodes on a distal end of the electrosurgical wand, each of the plurality of active electrodes intermittently exposed to a rectifying electrical phenomenon (block 902). The method further comprises charging a first capacitance in series with a first electrode of the plurality of active electrodes (the charging during periods of time when the rectifying electrical phenomenon proximate the first electrode) (block 904), charging a second capacitance in series with a second electrode of the plurality of active electrodes (the charging during periods of time when the rectifying electrical phenomenon is proximate the second electrode) (block 906), and charging a third capacitance in series with a third electrode of the plurality of active electrodes (the charging during periods of time when the rectifying electrical phenomenon is proximate the third electrode) (block 908). And then, the method comprises discharging, through the first electrode, the first capacitance while simultaneously charging the second capacitance (block 910), and the illustrative method ends (block 912).


In vivo experiments prove that the change in capacitor configuration from a single lumped capacitance (as in FIG. 1A) to a set of discrete capacitances associated one each with each electrode (as in FIG. 1B) results in a noticeable reduction in low frequency stimulation in the animal analogue (e.g., chicken) as the number of discrete capacitances increases. For example, the most significant effect was observed when the single 50 nano-Farard (nF) capacitance was replaced with 23 discrete 2.2 nF capacitors. Experiments with three discrete capacitors (on 10 nF and two 20 nF) shows improvement over the single 50 nF capacitor set-up, but with the results less pronounced than the 23 discrete 2.2 nF capacitor set up.


While preferred embodiments of this disclosure have been shown and described, modifications thereof can be made by one skilled in the art without departing from the scope or teaching herein. The embodiments described herein are exemplary only and are not limiting. Because many varying and different embodiments may be made within the scope of the present inventive concept, including equivalent structures, materials, or methods hereafter though of, and because many modifications may be made in the embodiments herein detailed in accordance with the descriptive requirements of the law, it is to be understood that the details herein are to be interpreted as illustrative and not in a limiting sense.

Claims
  • 1. A method of reducing muscle stimulation during electrosurgical procedures comprising: treating a target tissue with an electrosurgical wand comprising a plurality of active electrodes on a distal end of the electrosurgical wand, each of the plurality of active electrodes intermittently exposed to a rectifying electrical phenomenon;charging a first capacitance in series with a first electrode of the plurality of active electrodes, the charging during periods of time when the rectifying electrical phenomenon is proximate the first electrode;charging a second capacitance, distinct from the first capacitance, the second capacitance in series with a second electrode of the plurality of active electrodes, the charging during periods of time when the rectifying electrical phenomenon is proximate the second electrode;charging a third capacitance, distinct from the first and second capacitances, the third capacitance in series with a third electrode of the plurality of active electrodes, the charging during periods of time when the rectifying electrical phenomenon is proximate the third electrode; and thendischarging, through the first electrode, the first capacitance, during the step of charging the second capacitance.
  • 2. The method of claim 1, further comprising then discharging, through the second electrode, the second capacitance, during the step of charging the third capacitance.
  • 3. The method of claim 2, further comprising then discharging, through the third electrode, the third capacitance, during the step of charging the first capacitance.
  • 4. The method of claim 1 wherein the charging of the first capacitance further comprises charging the first capacitance disposed within an enclosure that encloses a voltage generator electrically coupled to the plurality of active electrodes.
  • 5. The method of claim 1 wherein the charging of the first, second and third capacitances further comprises charging the first, second and third capacitances disposed within an enclosure that encloses a voltage generator electrically coupled to the plurality of active electrodes.
  • 6. The method of claim 1 wherein the charging of the first capacitance further comprises charging the first capacitance disposed within at least one selected from the group consisting of: a handle of the wand; and an elongate shaft of the wand.
  • 7. The method of claim 1 wherein the charging of the first, second and third capacitances further comprises charging the first, second and third capacitances each disposed within at least one selected from the group consisting of: a handle of the wand; and an elongate shaft of the wand.
  • 8. The method of claim 1 wherein the charging of the first capacitance further comprises charging the first capacitance disposed within an multi-conductor cable, the multi-conductor cable couples the plurality of active electrodes of the wand to a voltage generator.
US Referenced Citations (502)
Number Name Date Kind
2050904 Trice Apr 1936 A
2056377 Wappler Oct 1939 A
2611365 Rubens Sep 1952 A
3434476 Shaw et al. Mar 1969 A
3633425 Sanford Jan 1972 A
3707149 Hao et al. Dec 1972 A
3718617 Royal Feb 1973 A
3815604 O'Malley et al. Jun 1974 A
3828780 Morrison, Jr. et al. Aug 1974 A
3901242 Storz Aug 1975 A
3920021 Hiltebrandt Nov 1975 A
3939839 Curtiss Feb 1976 A
3963030 Newton Jun 1976 A
3964487 Judson Jun 1976 A
3970088 Morrison Jul 1976 A
4033351 Hetzel Jul 1977 A
4040426 Morrison, Jr. Aug 1977 A
4043342 Morrison, Jr. Aug 1977 A
4074718 Morrison, Jr. Feb 1978 A
4092986 Schneiderman Jun 1978 A
D249549 Pike Sep 1978 S
4114623 Meinke et al. Sep 1978 A
4116198 Roos Sep 1978 A
4181131 Ogiu Jan 1980 A
4184492 Meinke et al. Jan 1980 A
4202337 Hren et al. May 1980 A
4228800 Degler, Jr. et al. Oct 1980 A
4232676 Herczog Nov 1980 A
4240441 Khalil Dec 1980 A
4248231 Herczog et al. Feb 1981 A
4301801 Schneiderman Nov 1981 A
4326529 Doss et al. Apr 1982 A
4346715 Gammell Aug 1982 A
4363324 Kusserow Dec 1982 A
4378801 Oosten Apr 1983 A
4381007 Doss Apr 1983 A
4418692 Guay Dec 1983 A
4474179 Koch Oct 1984 A
4476862 Pao Oct 1984 A
4509532 DeVries Apr 1985 A
4520818 Mickiewicz Jun 1985 A
4532924 Auth et al. Aug 1985 A
4548207 Reimels Oct 1985 A
4567890 Ohta et al. Feb 1986 A
4572206 Geddes et al. Feb 1986 A
4580557 Hertzmann Apr 1986 A
4587975 Salo et al. May 1986 A
4590934 Malis et al. May 1986 A
4593691 Lindstrom et al. Jun 1986 A
4658817 Hardy Apr 1987 A
4660571 Hess et al. Apr 1987 A
4674499 Pao Jun 1987 A
4682596 Bales et al. Jul 1987 A
4706667 Roos Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4727874 Bowers et al. Mar 1988 A
4750902 Wuchinich et al. Jun 1988 A
4765331 Petruzzi et al. Aug 1988 A
4785823 Eggers et al. Nov 1988 A
4805616 Pao Feb 1989 A
4823791 D'Amelio et al. Apr 1989 A
4832048 Cohen May 1989 A
4846179 O'Conner Jul 1989 A
4860752 Turner Aug 1989 A
4898169 Norman et al. Feb 1990 A
4907589 Cosman Mar 1990 A
4920978 Colvin May 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4936301 Rexroth et al. Jun 1990 A
4943290 Rexroth et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4966597 Cosman Oct 1990 A
4967765 Turner et al. Nov 1990 A
4976711 Parins et al. Dec 1990 A
4979948 Geddes et al. Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5007908 Rydell Apr 1991 A
5009656 Reimels Apr 1991 A
5026387 Thomas Jun 1991 A
5035696 Rydell Jul 1991 A
5047026 Rydell Sep 1991 A
5047027 Rydell Sep 1991 A
5057105 Malone et al. Oct 1991 A
5057106 Kasevich et al. Oct 1991 A
5078717 Parins et al. Jan 1992 A
5080660 Buelna Jan 1992 A
5083565 Parins et al. Jan 1992 A
5084044 Quint Jan 1992 A
5085659 Rydell Feb 1992 A
5088997 Delahuerga et al. Feb 1992 A
5092339 Geddes et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5099840 Goble Mar 1992 A
5102410 Dressel Apr 1992 A
5108391 Flachenecker et al. Apr 1992 A
RE33925 Bales et al. May 1992 E
5112330 Nishigaki et al. May 1992 A
5122138 Manwaring Jun 1992 A
5125928 Parins et al. Jun 1992 A
5156151 Imran Oct 1992 A
5167659 Ohtomo et al. Dec 1992 A
5171311 Rydell et al. Dec 1992 A
5174304 Latina et al. Dec 1992 A
5178620 Eggers et al. Jan 1993 A
5183338 Wickersheim et al. Feb 1993 A
5190517 Zieve et al. Mar 1993 A
5192280 Parins Mar 1993 A
5195959 Smith Mar 1993 A
5197466 Marchosky et al. Mar 1993 A
5197963 Parins Mar 1993 A
5207675 Canady May 1993 A
5217457 Delahuerga et al. Jun 1993 A
5217459 Kamerling Jun 1993 A
5249585 Turner et al. Oct 1993 A
5255980 Thomas et al. Oct 1993 A
5261410 Alfano et al. Nov 1993 A
5267994 Gentelia et al. Dec 1993 A
5267997 Farin et al. Dec 1993 A
5273524 Fox et al. Dec 1993 A
5277201 Stern Jan 1994 A
5281216 Klicek Jan 1994 A
5281218 Imran Jan 1994 A
5282799 Rydell Feb 1994 A
5290282 Casscells Mar 1994 A
5300069 Hunsberger et al. Apr 1994 A
5306238 Fleenor Apr 1994 A
5312400 Bales et al. May 1994 A
5314406 Arias et al. May 1994 A
5318563 Malis et al. Jun 1994 A
5324254 Phillips Jun 1994 A
5330470 Hagen Jul 1994 A
5334140 Philips Aug 1994 A
5334183 Wuchinich Aug 1994 A
5334193 Nardella Aug 1994 A
5336220 Ryan et al. Aug 1994 A
5342357 Nardella Aug 1994 A
5348554 Imran et al. Sep 1994 A
5363324 Hashimoto et al. Nov 1994 A
5366443 Eggers et al. Nov 1994 A
5370675 Edwards et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5375588 Yoon Dec 1994 A
5380277 Phillips Jan 1995 A
5380316 Aita Jan 1995 A
5383874 Jackson et al. Jan 1995 A
5383876 Nardella Jan 1995 A
5383917 Desai et al. Jan 1995 A
5389096 Aita Feb 1995 A
5395312 Desai Mar 1995 A
5400267 Denen et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5417687 Nardella et al. May 1995 A
5419767 Eggers et al. May 1995 A
5423810 Goble et al. Jun 1995 A
5423882 Jackman et al. Jun 1995 A
5436566 Thompson et al. Jul 1995 A
5437662 Nardella Aug 1995 A
5438302 Goble Aug 1995 A
5441499 Fritzsch Aug 1995 A
5449356 Walbrink et al. Sep 1995 A
5451224 Goble et al. Sep 1995 A
5454809 Janssen Oct 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5472443 Cordis et al. Dec 1995 A
5486161 Lax et al. Jan 1996 A
5496312 Klicek Mar 1996 A
5496314 Eggers Mar 1996 A
5496317 Goble et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5507743 Edwards et al. Apr 1996 A
5514130 Baker May 1996 A
5540683 Ichikawa et al. Jul 1996 A
5542915 Edwards et al. Aug 1996 A
5549598 O'Donnell, Jr. Aug 1996 A
5554152 Aita Sep 1996 A
5556397 Long et al. Sep 1996 A
5562703 Desai Oct 1996 A
5569242 Lax et al. Oct 1996 A
5571100 Goble et al. Nov 1996 A
5573533 Strul Nov 1996 A
5584872 LaFontaine et al. Dec 1996 A
5588960 Edwards et al. Dec 1996 A
5599350 Schulze et al. Feb 1997 A
5609151 Mulier et al. Mar 1997 A
5633578 Eggers et al. May 1997 A
5634921 Hood et al. Jun 1997 A
5643304 Schechter et al. Jul 1997 A
5647869 Goble et al. Jul 1997 A
5658278 Imran et al. Aug 1997 A
5660567 Nierlich et al. Aug 1997 A
5662680 Desai Sep 1997 A
5676693 LaFontaine et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5697927 Imran et al. Dec 1997 A
5700262 Acosta et al. Dec 1997 A
5715817 Steven-Wright et al. Feb 1998 A
5722975 Edwards et al. Mar 1998 A
5725524 Mulier et al. Mar 1998 A
5749869 Lindenmeier et al. May 1998 A
5749871 Hood et al. May 1998 A
5749914 Janssen May 1998 A
5755753 Knowlton May 1998 A
5766153 Eggers et al. Jun 1998 A
5769847 Panescu et al. Jun 1998 A
5785705 Baker Jul 1998 A
5786578 Christy et al. Jul 1998 A
5800429 Edwards Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5810809 Rydell Sep 1998 A
5836875 Webster, Jr. Nov 1998 A
5836897 Sakurai et al. Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5860951 Eggers Jan 1999 A
5860974 Abele Jan 1999 A
5860975 Goble et al. Jan 1999 A
5871469 Eggers et al. Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5873877 McGaffigan Feb 1999 A
5885277 Korth Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5891134 Goble et al. Apr 1999 A
5897553 Mulier Apr 1999 A
5902272 Eggers et al. May 1999 A
5944715 Goble et al. Aug 1999 A
5954716 Sharkey et al. Sep 1999 A
5964786 Ochs et al. Oct 1999 A
6004319 Goble et al. Dec 1999 A
6013076 Goble et al. Jan 2000 A
6015406 Goble et al. Jan 2000 A
6024733 Eggers et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6039734 Goble et al. Mar 2000 A
6047700 Eggers et al. Apr 2000 A
6056746 Goble et al. May 2000 A
6063079 Hovda et al. May 2000 A
6066134 Eggers et al. May 2000 A
6066489 Fields et al. May 2000 A
6068628 Fanton et al. May 2000 A
6074386 Goble et al. Jun 2000 A
6086585 Hovda et al. Jul 2000 A
6090106 Goble et al. Jul 2000 A
6090107 Borgmeier et al. Jul 2000 A
6093186 Goble et al. Jul 2000 A
6102046 Weinstein et al. Aug 2000 A
6105581 Eggers et al. Aug 2000 A
6109268 Thapliyal et al. Aug 2000 A
6117109 Eggers et al. Sep 2000 A
6126682 Sharkey et al. Oct 2000 A
6135999 Fanton et al. Oct 2000 A
6142992 Cheng et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6156334 Meyer-ingold et al. Dec 2000 A
6159194 Eggers et al. Dec 2000 A
6159208 Hovda et al. Dec 2000 A
6162217 Kannenberg et al. Dec 2000 A
6168593 Sharkey et al. Jan 2001 B1
6174309 Wrublewski et al. Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6179836 Eggers et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6190381 Olsen et al. Feb 2001 B1
6197021 Panescu et al. Mar 2001 B1
6203542 Ellsberry et al. Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6210405 Goble et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6228078 Eggers May 2001 B1
6228081 Goble May 2001 B1
6235020 Cheng et al. May 2001 B1
6237604 Burnside et al. May 2001 B1
6238391 Olsen et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6241723 Heim et al. Jun 2001 B1
6249706 Sobota et al. Jun 2001 B1
6254600 Willink et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6261286 Goble et al. Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264652 Eggers et al. Jul 2001 B1
6270460 McCartan et al. Aug 2001 B1
6277112 Underwood et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6283961 Underwood et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6306134 Goble et al. Oct 2001 B1
6308089 von der Rur et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6319007 Livaditis Nov 2001 B1
6322549 Eggers et al. Nov 2001 B1
6346104 Daly et al. Feb 2002 B2
6346107 Cucin Feb 2002 B1
6355032 Hovda et al. Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6364877 Goble et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6391025 Weinstein et al. May 2002 B1
6409722 Hoey et al. Jun 2002 B1
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6416509 Goble et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6432103 Ellsberry et al. Aug 2002 B1
6440129 Simpson Aug 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6468275 Wampler et al. Oct 2002 B1
6482201 Olsen et al. Nov 2002 B1
6500173 Underwood et al. Dec 2002 B2
6514248 Eggers et al. Feb 2003 B1
6514250 Jahns et al. Feb 2003 B1
6517498 Burbank et al. Feb 2003 B1
6530922 Cosman Mar 2003 B2
6558382 Jahns et al. May 2003 B2
6565560 Goble et al. May 2003 B1
6578579 Burnside Jun 2003 B2
6589237 Woloszko et al. Jul 2003 B2
6602248 Sharps et al. Aug 2003 B1
6620156 Garito et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6635034 Cosmescu Oct 2003 B1
6640128 Vilsmeier et al. Oct 2003 B2
6656177 Truckai et al. Dec 2003 B2
6663554 Babaev Dec 2003 B2
6663627 Francischelli et al. Dec 2003 B2
6702810 McClurken et al. Mar 2004 B2
6730080 Harano et al. May 2004 B2
6746447 Davison et al. Jun 2004 B2
6749604 Eggers et al. Jun 2004 B1
6749608 Garito et al. Jun 2004 B2
D493530 Reschke Jul 2004 S
6770071 Woloszko et al. Aug 2004 B2
6780178 Palanker et al. Aug 2004 B2
6780180 Goble et al. Aug 2004 B1
6780184 Tanrisever Aug 2004 B2
6802842 Ellman et al. Oct 2004 B2
6830558 Flaherty et al. Dec 2004 B2
6837887 Woloszko et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6855143 Davison et al. Feb 2005 B2
6864686 Novak et al. Mar 2005 B2
6866671 Tierney et al. Mar 2005 B2
6872183 Sampson et al. Mar 2005 B2
6878149 Gatto Apr 2005 B2
6890307 Kokate et al. May 2005 B2
6892086 Russell May 2005 B2
6911027 Edwards et al. Jun 2005 B1
6920883 Bessette et al. Jul 2005 B2
6921398 Carmel et al. Jul 2005 B2
6929640 Underwood et al. Aug 2005 B1
6949096 Davison et al. Sep 2005 B2
6953461 McClurken et al. Oct 2005 B2
6960204 Eggers et al. Nov 2005 B2
6974453 Woloszko et al. Dec 2005 B2
6979328 Baerveldt et al. Dec 2005 B2
6979601 Marr et al. Dec 2005 B2
6984231 Goble et al. Jan 2006 B2
6986770 Hood Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
7001382 Gallo Feb 2006 B2
7004941 Tvinnereim et al. Feb 2006 B2
7010353 Gan et al. Mar 2006 B2
7041102 Truckai et al. May 2006 B2
7070596 Woloszko et al. Jul 2006 B1
7090672 Underwood et al. Aug 2006 B2
7094215 Davison et al. Aug 2006 B2
7094231 Ellman et al. Aug 2006 B1
7104986 Hovda et al. Sep 2006 B2
7115139 McClurken et al. Oct 2006 B2
7131969 Hovda et al. Nov 2006 B1
7169143 Eggers et al. Jan 2007 B2
7179255 Lettice et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7192428 Eggers et al. Mar 2007 B2
7201750 Eggers et al. Apr 2007 B1
7217268 Eggers et al. May 2007 B2
7223265 Keppel May 2007 B2
7241293 Davison Jul 2007 B2
7247155 Hoey et al. Jul 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7270659 Hovda et al. Sep 2007 B2
7270661 Dahla et al. Sep 2007 B2
7271363 Lee et al. Sep 2007 B2
7276061 Schaer et al. Oct 2007 B2
7276063 Davison et al. Oct 2007 B2
7278994 Goble Oct 2007 B2
7282048 Goble et al. Oct 2007 B2
7297143 Woloszko et al. Nov 2007 B2
7297145 Ormsby et al. Nov 2007 B2
7318823 Sharps et al. Jan 2008 B2
7331956 Hovda et al. Feb 2008 B2
7335199 Goble et al. Feb 2008 B2
RE40156 Sharps et al. Mar 2008 E
7344532 Goble et al. Mar 2008 B2
7357798 Sharps et al. Apr 2008 B2
7387625 Hovda et al. Jun 2008 B2
7419488 Ciarrocca et al. Sep 2008 B2
7429260 Underwood et al. Sep 2008 B2
7429262 Woloszko et al. Sep 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7442191 Hovda et al. Oct 2008 B2
7445618 Eggers et al. Nov 2008 B2
7449021 Underwood et al. Nov 2008 B2
7462178 Woloszko et al. Dec 2008 B2
7468059 Eggers et al. Dec 2008 B2
7491200 Underwood et al. Feb 2009 B2
7507236 Eggers et al. Mar 2009 B2
7527624 Dubnack et al. May 2009 B2
7572251 Davison et al. Aug 2009 B1
7632267 Dahla Dec 2009 B2
7678069 Baker et al. Mar 2010 B1
7691101 Davison et al. Apr 2010 B2
7699830 Martin Apr 2010 B2
7722601 Wham et al. May 2010 B2
7785322 Penny et al. Aug 2010 B2
7824398 Woloszko et al. Nov 2010 B2
7862560 Marion Jan 2011 B2
7985072 Belikov et al. Jul 2011 B2
D658760 Cox et al. May 2012 S
8192424 Woloszko Jun 2012 B2
8257350 Marion Sep 2012 B2
8372067 Woloszko et al. Feb 2013 B2
20020029036 Goble et al. Mar 2002 A1
20020042612 Hood et al. Apr 2002 A1
20020151882 Marko et al. Oct 2002 A1
20020183739 Long Dec 2002 A1
20030013986 Saadat Jan 2003 A1
20030014045 Russell Jan 2003 A1
20030014047 Woloszko et al. Jan 2003 A1
20030088245 Woloszko et al. May 2003 A1
20030130655 Woloszko et al. Jul 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030171743 Tasto et al. Sep 2003 A1
20030181903 Hood et al. Sep 2003 A1
20030208196 Stone Nov 2003 A1
20030212396 Eggers et al. Nov 2003 A1
20030216725 Woloszko et al. Nov 2003 A1
20030216732 Truckai et al. Nov 2003 A1
20030232048 Yang et al. Dec 2003 A1
20040030330 Brassell et al. Feb 2004 A1
20040116922 Hovda et al. Jun 2004 A1
20040127893 Hovda Jul 2004 A1
20040186418 Karashima Sep 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20050004634 Hovda et al. Jan 2005 A1
20050033278 McClurken et al. Feb 2005 A1
20050119650 Sanders et al. Jun 2005 A1
20050245923 Christopherson et al. Nov 2005 A1
20050251134 Woloszko et al. Nov 2005 A1
20050261754 Woloszko et al. Nov 2005 A1
20050273091 Booth et al. Dec 2005 A1
20050288665 Woloszko et al. Dec 2005 A1
20060036237 Davison et al. Feb 2006 A1
20060095031 Ormsby May 2006 A1
20060161148 Behnke Jul 2006 A1
20060178670 Woloszko et al. Aug 2006 A1
20060189971 Eggers et al. Aug 2006 A1
20060253117 Hovda et al. Nov 2006 A1
20060259025 Dahla Nov 2006 A1
20070106288 Woloszko et al. May 2007 A1
20070149966 Dahla et al. Jun 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070208334 Woloszko et al. Sep 2007 A1
20070208335 Woloszko et al. Sep 2007 A1
20070282323 Woloszko et al. Dec 2007 A1
20080004621 Dahla et al. Jan 2008 A1
20080077128 Woloszko et al. Mar 2008 A1
20080138761 Pond Jun 2008 A1
20080140069 Filloux et al. Jun 2008 A1
20080154255 Panos et al. Jun 2008 A1
20080167645 Woloszko Jul 2008 A1
20080234671 Marion Sep 2008 A1
20080243116 Anderson Oct 2008 A1
20080300590 Horne et al. Dec 2008 A1
20090209956 Marion Aug 2009 A1
20090222001 Greeley Sep 2009 A1
20090318915 Hosier et al. Dec 2009 A1
20100152726 Cadouri et al. Jun 2010 A1
20100228246 Marion Sep 2010 A1
20100292689 Davison et al. Nov 2010 A1
20100318083 Davison et al. Dec 2010 A1
20120083782 Stalder et al. Apr 2012 A1
20120095453 Cox et al. Apr 2012 A1
20120095454 Cox et al. Apr 2012 A1
20120109123 Woloszko et al. May 2012 A1
20120196251 Taft et al. Aug 2012 A1
20120197344 Taft et al. Aug 2012 A1
20120215221 Woloszko Aug 2012 A1
20120296328 Marion Nov 2012 A1
Foreign Referenced Citations (74)
Number Date Country
3119735 Jan 1983 DE
3930451 Mar 1991 DE
423757 Mar 1996 EP
0703461 Mar 1996 EP
0740926 Nov 1996 EP
0754437 Jan 1997 EP
0694290 Nov 2000 EP
1334699 Aug 2003 EP
1428480 Jun 2004 EP
1707147 Oct 2006 EP
2313949 Jan 1977 FR
467502 Jun 1937 GB
2160102 Dec 1985 GB
2299216 Sep 1996 GB
2 308 979 Jul 1997 GB
2 308 980 Jul 1997 GB
2 308 981 Jul 1997 GB
2 327 350 Jan 1999 GB
2 327 351 Jan 1999 GB
2 327 352 Jan 1999 GB
2333455 Jul 1999 GB
2406793 Apr 2005 GB
57-57802 Apr 1982 JP
57-117843 Jul 1982 JP
9003152 Apr 1990 WO
9007303 Jul 1990 WO
9221278 Dec 1992 WO
9313816 Jul 1993 WO
9320747 Oct 1993 WO
9404220 Mar 1994 WO
9408654 Apr 1994 WO
9410921 May 1994 WO
9426228 Nov 1994 WO
9534259 Dec 1995 WO
9600040 Jan 1996 WO
9600042 Jan 1996 WO
9639086 Dec 1996 WO
9700646 Jan 1997 WO
9700647 Jan 1997 WO
9718768 May 1997 WO
9724073 Jul 1997 WO
9724074 Jul 1997 WO
9724993 Jul 1997 WO
9724994 Jul 1997 WO
9743971 Nov 1997 WO
9748345 Dec 1997 WO
9748346 Dec 1997 WO
9807468 Feb 1998 WO
9826724 Jun 1998 WO
9827879 Jul 1998 WO
9827880 Jul 1998 WO
9856324 Dec 1998 WO
9920213 Apr 1999 WO
9951155 Oct 1999 WO
9951158 Oct 1999 WO
9956648 Nov 1999 WO
0000098 Jan 2000 WO
0009053 Feb 2000 WO
0062685 Oct 2000 WO
0124720 Apr 2001 WO
0187154 May 2001 WO
0195819 Dec 2001 WO
0236028 May 2002 WO
02102255 Dec 2002 WO
03024305 Mar 2003 WO
03092477 Nov 2003 WO
2004026150 Apr 2004 WO
2004071278 Aug 2004 WO
2005125287 Dec 2005 WO
2007006000 Jan 2007 WO
2007056729 May 2007 WO
2010052717 May 2010 WO
2012050636 Apr 2012 WO
2012050637 Apr 2012 WO
Non-Patent Literature Citations (108)
Entry
Barry et al., “The Effect of Radiofrequency-generated Thermal Energy on the Mechanical and Histologic Characteristics of the Arterial Wall in Vivo: Implications of Radiofrequency Angioplasty” American Heart Journal vol. 117, pp. 332-341, 1982.
BiLAP Generator Settings, Jun. 1991.
BiLAP IFU 910026-001 Rev A for BiLAP Model 3525, J-Hook, 4 pgs, May 20, 1991.
BiLAP IFU 910033-002 Rev A for BiLAP Model 3527, L-Hook; BiLAP Model 3525, J-Hook; BiLAP Model 3529, High Angle, 2 pgs, Nov. 30, 1993.
Codman & Shurtleff, Inc. “The Malis Bipolar Coagulating and Bipolar Cutting System CMC-II” brochure, early, 2 pgs, 1991.
Codman & Shurtleff, Inc. “The Malis Bipolar Electrosurgical System CMC-III Instruction Manual” , 15 pgs, Jul. 1991.
Cook et al., “Therapeutic Medical Devices: Application and Design”, Prentice Hall, Inc., 3pgs, 1982.
Dennis et al. “Evolution of Electrofulguration in Control of Bleeding of Experimental Gastric Ulcers,” Digestive Diseases and Sciences, vol. 24, No. 11, 845-848, Nov. 1979.
Dobbie, A.K., “The Electrical Aspects of Surgical Diathermy, Bio Medical Engineering” Bio-Medical Engineering vol. 4, pp. 206-216, May 1969.
Elsasser, V.E. et al., “An Instrument for Transurethral Resection without Leakage of Current” Acta Medicotechnica vol. 24, No. 4, pp. 129-134, 1976.
Geddes, “Medical Device Accidents: With Illustrative Cases” CRC Press, 3 pgs, 1998.
Honig, W., “The Mechanism of Cutting in Electrosurgery” IEEE pp. 58-65, 1975.
Kramolowsky et al. “The Urological App of Electorsurgery” J. of Urology vol. 146, pp. 669-674, 1991.
Kramolowsky et al. “Use of 5F Bipolar Electrosurgical Probe in Endoscopic Urological Procedures” J. of Urology vol. 143, pp. 275-277, 1990.
Lee, B et al. “Thermal Compression and Molding of Artherosclerotic Vascular Tissue with Use” JACC vol. 13(5), pp. 1167-1171, 1989.
Letter from Department of Health to Jerry Malis dated Jan. 24, 1991, 3 pgs.
Letter from Department of Health to Jerry Malis dated Jul. 25, 1985, 1 pg.
Letter from Jerry Malis to FDA dated Jul. 25, 1985, 2 pgs.
Lu, et al., “Electrical Thermal Angioplasty: Catheter Design Features, In Vitro Tissue Ablation Studies and In Vitro Experimental Findings,” Am J. Cardiol vol. 60, pp. 1117-1122, Nov. 1, 1987.
Malis, L., “Electrosurgery, Technical Note,” J. Neursurg., vol. 85, pp. 970-975, Nov. 1996.
Malis, L., “Excerpted from a seminar by Leonard I. Malis, M.D. at the 1995 American Association of Neurological Surgeons Meeting,” 1pg, 1995.
Malis, L., “Instrumentation for Microvascular Neurosurgery” Cerebrovascular Surgery, vol. 1, pp. 245-260, 1985.
Malis, L., “New Trends in Microsurgery and Applied Technology,” Advanced Technology in Neurosurgery, pp. 1-16, 1988.
Malis, L., “The Value of Irrigation During Bipolar Coagulation” See ARTC 21602, 1 pg, Apr. 9, 1993.
Nardella, P.C., SPIE 1068: pp. 42-49, Radio Frequency Energy and Impedance Feedback, 1989.
O'Malley, Schaum's Outline of Theory and Problems of Basic Circuit Analysis, McGraw-Hill, 2nd Ed., pp. 3-5, 1992.
Olsen MD, Bipolar Laparoscopic Cholecstectomy Lecture (marked confidential), 12 pgs, Oct. 7, 1991.
Pearce, John A. “Electrosurgery”, pp. 17, 69-75, 87, John Wiley & Sons, New York, 1986.
Pearce, John A., “Electrosurgery”, Handbook of Biomedical Engineering, chapter 3, Academic Press Inc., N.Y., pp. 98-113, 1988.
Piercey et al., “Electrosurgical Treatment of Experimental Bleeding Canine Gastric Ulcers” Gastroenterology vol. 74(3), pp. 527-534, 1978.
Protell et al., “Computer-Assisted Electrocoagulation: Bipolar v. Monopolar in the Treatment of Experimental Canine Gastric Ulcer Bleeding,” Gastroenterology vol. 80, No. 3, pp. 451-455, 1981.
Ramsey et al., “A Comparison of Bipolar and Monopolar Diathermy Probes in Experimental Animals”, Urological Research vol. 13, pp. 99-102, 1985.
Selikowitz et al., “Electric Current and Voltage Recordings on the Myocardium During Electrosurgical Procedures in Canines,” Surgery, Gynecology & Obstetrics, vol. 164, pp. 219-224, Mar. 1987.
Shuman, “Bipolar Versus Monopolar Electrosurgery: Clinical Applications,” Dentistry Today, vol. 20, No. 12, 7 pgs, Dec. 2001.
Slager et al. “Spark Erosion of Arteriosclerotic Plaques” Z. Kardiol. 76:Suppl. 6, pp. 67-71, 1987.
Slager et al. “Vaporization of Atherosclerotice Plaques by Spark Erosion” JACC 5(6): pp. 1382-1386, Jun. 1985.
Stoffels, E. et al., “Investigation on the Interaction Plasma-Bone Tissue”, E-MRS Spring Meeting, 1 pg, Jun. 18-21, 2002.
Stoffels, E. et al., “Biomedical Applications of Plasmas”, Tutorial presented prior to the 55th Gaseous Electronics Conference in Minneapolis, MN, 41 pgs, Oct. 14, 2002.
Stoffels, E. et al., “Plasma Interactions with Living Cells”, Eindhoven University of Technology, 1 pg, 2002.
Stoffels, E. et al., “Superficial Treatment of Mammalian Cells using Plasma Needle”, J. Phys. D: Appl. Phys. 26, pp. 2908-2913, Nov. 19, 2003.
Stoffels, E. et al., “Plasma Needle”, Eindhoven University of Technology, 1 pg, Nov. 28, 2003.
Stoffels, E. et al., “Plasma Physicists Move into Medicine”, Physicsweb, 1 pg, Nov. 2003.
Stoffels, E. et al., “Plasma Treated Tissue Engineered Skin to Study Skin Damage”, Biomechanics and Tissue Engineering, Materials Technology, 1 pg, 2003.
Stoffels, E. et al., “Plasma Treatment of Dental Cavities: A Feasibility Study”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1540-1542, Aug. 2004.
Stoffels, E. et al., “The Effects of UV Irradiation and Gas Plasma Treatment on Living Mammalian Cells and Bacteria: A Comparative Approach”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1544-1550, Aug. 2004.
Stoffels, E. et al., “Electrical and Optical Characterization of the Plasma Needle”, New Journal of Physics 6, pp. 1-14, Oct. 28, 2004.
Stoffels, E. et al., “Where Plasma Meets Plasma”, Eindhoven University of Technology, 23 pgs, 2004.
Stoffels, E. et al., “Gas Plasma effects on Living Cells”, Physica Scripta, T107, pp. 79-82, 2004.
Stoffels, E. et al., “Plasma Treatment of Mammalian Vascular Cells: A Quantitative Description”, IEEE Transaction on Plasma Science, vol. 33, No. 2, pp. 771-775, Apr. 2005.
Stoffels, E. et al., “Deactivation of Escherichia coli by the Plasma Needle”, J. Phys. D: Appl. Phys. 38, pp. 1716-1721, May 20, 2005.
Stoffels, E. et al., “Development of a Gas Plasma Catheter for Gas Plasma Surgery”, XXVIIth ICPIG, Endoven University of Technology, pp. 18-22, Jul. 2005.
Stoffels, E. et al., “Development of a Smart Positioning Sensor for the Plasma Needle”, Plasma Sources Sci. Technol. 15, pp. 582-589, Jun. 27, 2006.
Stoffels, E. et al., Killing of S. Mutans Bacteria Using a Plasma Needle at Atmospheric Pressure, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1317-1324, Aug. 2006.
Stoffels, E. et al., “Plasma-Needle Treatment of Substrates with Respect to Wettability and Growth of Excherichia coli and Streptococcus mutans”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1325-1330, Aug. 2006.
Stoffels, E. et al., “Reattachment and Apoptosis after Plasma-Needle Treatment of Cultured Cells”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1331-1336, Aug. 2006.
Stoffels, E. et al., “UV Excimer Lamp Irradiation of Fibroblasts: The Influence on Antioxidant Homostasis”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1359-1364, Aug. 2006.
Stoffels, E. et al., “Plasma Needle for In Vivo Medical Treatment: Recent Developments and Perspectives”, Plasma Sources Sci. Technol. 15, pp. S169-S180, Oct. 6, 2006.
Swain, C.P., et al., “Which Electrode, A Comparison of four endoscopic methods of electrocoagulation in experimental bleeding ulcers” Gut vol. 25, pp. 1424-1431, 1987.
Tucker, R. et al., Abstract P14-11, p. 248, “A Bipolar Electrosurgical Turp Loop”, Nov. 1989.
Tucker, R. et al. “A Comparison of Urologic Application of Bipolar Versus Monopolar Five French Electrosurgical Probes” J. of Urology vol. 141, pp. 662-665, 1989.
Tucker, R. et al. “In vivo effect of 5 French Bipolar and Monopolar Electrosurgical Probes on the Porcine Bladder” Urological Research vol. 18, pp. 291-294, 1990.
Tucker, R. et al., “Demodulated Low Frequency Currents from Electrosurgical Procedures,” Surgery, Gynecology and Obstetrics, 159:39-43, 1984.
Tucker et al. “The interaction between electrosurgical generators, endoscopic electrodes, and tissue,” Gastrointestinal Endoscopy, vol. 38, No. 2, pp. 118-122, 1992.
Valley Forge Scientific Corp., “Summary of Safety and Effective Information from 510K”, 2pgs, 1991.
Valley Forge's New Products, CLINICA, 475, 5, Nov. 6, 1991.
Valleylab SSE2L Instruction Manual, 11 pgs, Jan. 6, 1983.
Valleylab, Inc. “Valleylab Part No. 945 100 102 A” Surgistat Service Manual, pp. 1-46, Jul. 1988.
Wattiez, Arnaud et al., “Electrosurgery in Operative Endoscopy,” Electrosurgical Effects, Blackwell Science, pp. 85-93, 1995.
Wyeth, “Electrosurgical Unit” pp. 1181-1202, 2000.
Buchelt, et al. “Excimer Laser Ablation of Fibrocartilage: An In Vitro and In Vivo Study”, Lasers in Surgery and Medicine, vol. 11, pp. 271-279, 1991.
Costello et al., “Nd: YAG Laser Ablation of the Prostate as a Treatment for Benign Prostatic Hypertrophy”, Lasers in Surgery and Medicine, vol. 12, pp. 121-124, 1992.
Rand et al., “Effect of Electrocautery on Fresh Human Articular Cartilage”, J. Arthro. Surg., vol. 1, pp. 242-246, 1985.
Slager et al., “Electrical nerve and Muscle Stimulation by Radio Frequency Surgery: Role of Direct Current Loops Around the Active Electrode”, IEEE Transactions on Biomedical engineering, vol. 40, No. 2, pp. 182-187, Feb. 1993.
European Examination Report for EP 02773432 4 pgs, Sep. 22, 2009.
European Examination Report for EP 05024974 4 pgs, Dec. 5, 2008.
European Examination Report for EP 04708664 7pgs, Sep. 7, 2009.
European Examination Report for EP 02749601.7 4pgs, Dec. 2, 2009.
European Search Report for EP 02773432 3pgs, Dec. 19, 2008.
European Search Report for EP 04708664.0 5pgs, Apr. 6, 2009.
European Search Report for EP 98953859, 2 pgs, Jul. 2, 2001.
Suppl European Search Report for EP 98953859, 3 pgs, Oct. 18, 2001
Extended European Search Report for EP09152846, 8pgs, Jan. 5, 2010.
European Search Report for EP 99945039.8, 3 pgs, Oct. 1, 2001.
PCT International Preliminary Examination Report for PCT/US02/19261, 3 pgs, Mar. 25, 2003.
PCT International Search Report for PCT/US02/19261, 1 pg, Mailed Sep. 18, 2002.
PCT International Search Report for PCT/US02/29476, 1 pg, Mailed May 24, 2004.
PCT International Search Report for PCT/US03/13686, 1 pg, Mailed Nov. 25, 2003.
PCT International Search Report for PCT/US04/03614, 1 pg, Mailed Sep. 14, 2004.
PCT International Search Report for PCT/US98/22323, 1 pg, Mailed Mar. 3, 1999.
PCT International Search Report for PCT/US99/14685, 1 pg, Mailed Oct. 21, 1999.
PCT International Search Report for PCT/US99/18289, 1 pg, Mailed Dec. 7, 1999.
PCT Notification of International Preliminary Examination Report for PCT/US98/22323, 5 pgs, Mailed Nov. 28, 2000.
PCT Notification of International Preliminary Examination Report for PCT/US99/14685, 4 pgs, Mailed Feb. 20, 2001.
PCT Notification of International Preliminary Examination Report for PCT/US99/18289, 4 pgs, Mailed Jul. 7, 2000.
PCT Notification of International Search Report and Written Opinion for PCT/US06/26321, 8pgs, Mailed Apr. 25, 2007.
PCT Notification of the International Search Report and Written Opinion for PCT/US06/60618, 7pgs, Mailed Oct. 5, 2007.
PCT Notification of the International Search Report and Written Opinion for PCT/US07/69856, 7pgs, Mailed Jun. 5, 2008.
PCT Written Opinion of the International Searching Authority for PCT/US04/03614, 4 pgs, Mailed Sep. 14, 2004.
UK Search Report for GB0800129.9 2pgs, May 8, 2008.
UK Search Report for GB0805062.7 1 pg, Jul. 16, 2008.
UK Search Report for GB0900604.0 4 pgs, May 15, 2009.
European Examination Report (2nd) for EP 04708664 5pgs, May 3, 2010.
European Examination Report (3rd) for EP 04708664 6pgs, Nov. 6, 2012.
European Search Report for EP 09152850, 2 pgs, Dec. 29, 2009.
PCT Notification of the International Search Report and Written Opinion for PCT/US2011/033784 11 pgs, Mailed Jul. 18, 2011.
PCT Notification of the International Search Report and Written Opinion for PCT/US2011/033761 11 pgs, Mailed Jul. 22, 2011.
UK Search Report for GB1110342.1 3pgs, Oct. 18, 2011.
UK Suppl Search Report for GB1110342.1 2pgs, Aug. 16, 2012.
Related Publications (1)
Number Date Country
20110245826 A1 Oct 2011 US